KALV - KalVista Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue8,3941,5042,1331,804
Cost of Revenue18,23712,66614,6618,285
Gross Profit-9,843-11,162-12,528-6,481
Operating Expenses
Research Development----
Selling General and Administrative8,8624,7772,6531,608
Non Recurring----
Total Operating Expenses27,09917,44317,3149,893
Operating Income or Loss-18,705-15,939-15,181-8,089
Income from Continuing Operations
Total Other Income/Expenses Net2,900-2,6643,745863
Earnings Before Interest and Taxes-18,705-15,939-15,181-8,089
Interest Expense----
Income Before Tax-15,805-18,603-11,436-7,226
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-15,805-18,603-11,436-7,226
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-15,805-18,603-11,436-7,226
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-15,805-20,775-15,475-9,203